# Clinical Trials Data EGFR - Document 61

# Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01048918

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients must be \\> 18 years old.\n\* Patients are being treated for breast cancer at City of Hope (COH).",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Brawerman Center-Outpatient clinics (City of Hope), Pasadena Satellite Office",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, there are no specific eligibility criteria mentioning gene mutations, such as an EGFR mutation, for inclusion in the trial. The key criteria are:  
  
1. Patients must be over 18 years old.  
2. Patients must be female.  
3. Patients must be receiving treatment for breast cancer at City of Hope (COH).  
  
Since the eligibility criteria do not specify exclusion or inclusion based on EGFR gene mutations, a patient with an EGFR gene mutation would still potentially be eligible, provided they meet the other inclusion criteria. It would be important to check with the trial administrators for any additional criteria not listed or any potential amendments that may impact eligibility.